Environmental, social and governance (ESG) imperatives impact every aspect of the work of clinical trial operations. The world is moving toward a greener economy – meaning that investors, financial institutions and the general public all want to see evidence of ESG activities associated with the funding they make available to organizations.
In this paper, Syneos Health ESG experts examine the how life sciences companies are being affected by these requirements. They investigate how clinical operations leaders can plan for their organization’s ESG priorities, while also being proactive in moving their organization forward.
Download the white paper.
